Liposome Drug Delivery Market Segmentation:
Application Segment Analysis
The cancer therapy segment in the liposome drug delivery market is anticipated to hold the largest revenue share of 41% by the end of 2035. This can be attributed to the growing demand for advanced therapeutics. According to the WHO 2020, cancer is a leading cause of death globally, accounting for approximately 10 million deaths in 2020, which means nearly one out of every six deaths were due to cancer. Liposomal formulations enhance drug stability and improve tumor penetration making them highly preferable for treating various cancers, further boosting market expansion.
Product Segment Analysis
The liposomal doxorubicin segment is anticipated to hold a 38% share of the global liposome drug delivery market by the end of 2035. This segment growth is attributed to its effectiveness in treating various cancers, including breast cancer, ovarian cancer, and multiple myeloma. The American Cancer Society states that AML accounts for about 1 out of 3 leukemias in adults. It further states that about 22,010 acute myeloid leukemia (AML) cases are projected to be registered in the U.S. in 2025, with approximately 11,090 people dying from the disease. Doxorubicin is used for treating several blood cancers, including AML and Hodgkin's lymphoma. Additionally, improved manufacturing technologies and regulatory support for liposomal formulations contribute to its wider adoption.
Our in-depth analysis of the global liposome drug delivery market includes the following segments:
|
Product |
|
|
Technology |
|
|
Application |
|
